Comparative study of effect of alpha glucosidase inhibitors-miglitol, acarbose and voglibose on postprandial hyperglycemia and glycosylated hemoglobin in type-2 diabetes mellitus

International Journal of Pharma and Bio Sciences

Volumn 3, Issue 3, 2012, Pages

  Ismail, Teli Shaikh Emaran Shaikh ^a   Deshmukh, Sarang Anantrao ^a  

^a Shri Bhausaheb Hire Government Medical College   (India)

Author keywords

Acarbose; Glycosylated haemoglobin; Miglitol; Postprandial hyperglycemia; Voglibose

Indexed keywords

ACARBOSE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; MIGLITOL; VOGLIBOSE;

ABDOMINAL PAIN; ANTIDIABETIC ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FLATULENCE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; POSTPRANDIAL HYPERGLYCEMIA; POSTPRANDIAL STATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 84867739437     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dr. Rajiv Gupta Diabetes in India: Current Status [Internet], Available from http://www.expresshealthcare.in/200808/di abetes02.shtml;(2008).
2. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia; 44:2107-14,(2001).
3. Stratton IM, Adler AI, Neil HA, et al. The UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321:405-12,(2000).
4. Gaster B, Hirsch IB. The effects of improved glycaemic control on complications in type 2 diabetes. Arch Intern Med, 158: 134-40,(1998).
5. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention, Ann Intern Med, 124(2): 123-6,(1996).
6. Kahn R.D. Postprandial Blood Glucose. Diabetes Care, 24 (4): 775-8,(2001).
7. Scott L J, Spencer C M. Miglitol: A review of its therapeutic potential in type I diabetes mellitus, Drugs, 59(3): 521-49,(2000).
8. Hanefield M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H et al. risk factors for myocardial infarction and death in newly detected NIDDM:The diabetes intervention study, 11 year follow up, Diabetologica,39:1577-83,(1996).
9. Markus R. Alpha glucosidase inhibitors. In Derek L., Simeon C., Olefsky J.M., Ed. Diabetes Mellitus-A fundamental and clinical text, 3rd Edn. Lippincott Williams and Wilkins publisher: 1151-56, (2004)
10. Mitrakou A, Tauntas N, Raptis AE, et.al. Long term effectiveness of a new alpha glucosidase inhibitol (Miglitol) in insulin treated type 2 diabetes mellitus. Diabetic medicine.,15:657-60,(1998).
11. Adiyodi JR, Acarbose: Revolutionising treatment of NIDDM. Diabetes Update:18-31, (1999).
12. Matsumoto K et al. Effect of Voglibose on glycemic excursion, insulin secretion and insulin sensitivity in non insulin treated NIDDM patients. Diabetes Care, 21(2):256-260,(1998)
13. Saino N et al. Effect of an alphaglucosidase inhibitor (Voglibose) in combination with sulfonylureas on glycemic control in type-2 diabetes patients. The J of International Medical Research, 26: 219-32,(1998)
14. Vichayanrat A. et al. Efficacy and safety of voglibose in comparison with acarbose in type II diabetes patients. Diabetes research and Clinical Practice,55: 99-103,(2002).
15. Van de Laar FA, Lucassen PLBJ, Alkermon R.P et al. Alpha glucosidase Inhibitors for type II diabetes mellitus. The Cochrane Central Registrar of Controlled Trials 2005/ 2: 56-182
16. Van de Laar FA, Lucassen PLBJ, Akkermans RP et al. Alpha-glucosidase inhibitors for type-2 diabetes mellitus (Review). The Cochrane Library, Issue 1:1-186(2007).